skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Photoaffinity cross-linking of a radioiodinated probe, /sup 125/I-A55453, into alpha 1-adrenergic receptors

Journal Article · · Mol. Pharmacol.; (United States)
OSTI ID:6137524

We have synthesized and characterized a high-affinity alpha 1-adrenergic receptor probe, 4-amino-6,7-dimethoxy-2(4'- (5''(3'''-/sup 125/I-iodo-4'''-aminophenyl)pentanoyl)-1'-piperazinyl) quinazoline (/sup 125/I-A55453). This ligand binds reversibly to rat hepatic plasma membranes with high affinity (KD . 77 +/- 6 pM), and it labels the same number of specific prazosin-competable sites as the alpha 1-adrenergic receptor-selective radioligand (/sup 125/I) iodo-2-(beta-(4-hydroxyphenyl)-ethylaminomethyl)tetralone. Specific binding is stereoselective and competed for by alpha-adrenergic agents with an alpha 1-adrenergic receptor specificity. /sup 125/I-A55453 can be covalently photoincorporated into peptides of rat hepatic and splenic membranes using the bifunctional photoactive cross-linker, N-succinimidyl-6- (4'-azido-2'-nitrophenylamino)hexanoate. Following photolysis, sodium dodecyl sulfate-polyacrylamide gel electrophoresis of labeled hepatic membranes reveals a major specifically labeled peptide of Mr . 82,000 (+/- 1,000) with minor peptides at Mr . 50,000 (+/- 500), and 40,000 (+/- 300). Covalent incorporation of /sup 125/I-A55453 into the Mr . 82,000 peptide is inhibited by adrenergic drugs with an alpha 1-adrenergic receptor specificity. Labeled splenic membranes demonstrate a broad band of photoincorporated radioactivity centered at Mr . 82,000, and covalent incorporation into this peptide is also attenuated with an alpha 1-adrenergic receptor specificity. This new high-affinity radioiodinated probe has features which should make it useful for the molecular characterization of alpha 1-adrenergic receptors in tissues.

Research Organization:
Duke Univ. Medical Center, Durham, NC
OSTI ID:
6137524
Journal Information:
Mol. Pharmacol.; (United States), Vol. 26:2
Country of Publication:
United States
Language:
English